Zobrazeno 1 - 10
of 32
pro vyhledávání: '"R, Mante"'
Publikováno v:
02.01 - Acute critical care.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9d8c8c995a6d553e6ad8b086eb92d985
https://doi.org/10.1183/13993003.congress-2022.1241
https://doi.org/10.1183/13993003.congress-2022.1241
Autor:
Debra Clayton-Krasinski, Christine Wade, Jennifer R. Mante, Veronica L. Rockett, Ted Marks, Thomas A. Hertel, Anne B. Belt
Publikováno v:
Pediatric Physical Therapy. 13:110-121
Purpose The purposes of this study were to: 1) determine if previously published descriptors of the supine to stand rising task in healthy individuals could be applied to the movements of persons with Prader-Willi Syndrome (PWS); and 2) assess upper
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7fc04c7d262e13a5883bc87201b46218
https://doi.org/10.1097/00001577-200110000-00003
https://doi.org/10.1097/00001577-200110000-00003
Autor:
H. R. Gibbs, M. Hord, Claire F. Verschraegen, Irwin H. Krakoff, Creighton L. Edwards, Andrzej P. Kudelka, John J. Kavanagh, R Mante, Ralph S. Freedman, Yu Shen, Arthur D. Forman, C. Gonzalez De Leon, R. Canetta
Publikováno v:
International Journal of Gynecological Cancer. 9:44-53
The purpose of this study was to analyze the efficacy and toxicity of a high dose of paclitaxel in patients with ovarian cancer refractory to platinum chemotherapy. Another phase II study of hydroxyurea was run in the same patient population. Fifty p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c000e64a952bb3678db38d79a819172f
https://doi.org/10.1046/j.1525-1438.1999.09856.x
https://doi.org/10.1046/j.1525-1438.1999.09856.x
Autor:
Creighton L. Edwards, Andrzej P. Kudelka, Geri L. Fromm, John J. Kavanagh, R Mante, Damrong Tresukosol
Publikováno v:
Gynecologic Oncology. 58:258-261
This Case Report describes a patient with primary fallopian tube cancer who had a late recurrence of pelvic disease following adjuvant chemotherapy for early-stage disease. Secondary cytoreductive surgery was suboptimal. The bulky residual disease wa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35bf5e42d023601f59ef6f0d390d917f
https://doi.org/10.1006/gyno.1995.1222
https://doi.org/10.1006/gyno.1995.1222
Autor:
R Mante, Ralph S. Freedman, Creighton L. Edwards, Andrzej P. Kudelka, John J. Kavanagh, Damrong Tresukosol, A. Fishman, M. Hord, C. Gonzalez De Leon
Publikováno v:
Journal of Clinical Oncology. 13:1584-1588
PURPOSE To determine the activity of carboplatin in patients with ovarian cancer who progressed on taxane (paclitaxel or docetaxel) therapy. PATIENTS AND METHODS Thirty-three patients with ovarian cancers refractory to platinum and taxane therapy wer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5afe0ef6dbcea466f254a104f3a38df
https://doi.org/10.1200/jco.1995.13.7.1584
https://doi.org/10.1200/jco.1995.13.7.1584
A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix
Autor:
A P, Kudelka, T, Levy, C F, Verschraegen, C L, Edwards, S, Piamsomboon, W, Termrungruanglert, R S, Freedman, A L, Kaplan, D G, Kieback, C A, Meyers, K A, Jaeckle, E, Loyer, M, Steger, R, Mante, G, Mavligit, A, Killian, R A, Tang, J U, Gutterman, J J, Kavanagh
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 3(9)
A Phase I study of the novel angiogenesis inhibitor TNP-470 was performed. Patients with inoperable recurring or metastatic squamous cell cancer of the cervix with evaluable disease, no coagulopathy, and adequate renal, hepatic, and hematological fun
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b519c6aca3b95e7ea67078aa10882b35
https://pubmed.ncbi.nlm.nih.gov/9815836
https://pubmed.ncbi.nlm.nih.gov/9815836
Autor:
Ram Rastogi, Damrong Tresukosol, Timothy Madden, Carmen Tornos, Andrzej P. Kudelka, Ralph S. Freedman, Creighton L. Edwards, R Mante, John J. Kavanagh, E. Edmund Kim, Zahid H. Siddik, M. Hord
Publikováno v:
Anti-cancer drugs. 8(7)
This was a study of enloplatin in 18 evaluable patients with platinum refractory ovarian cancer. They received an i.v. infusion of enloplatin over 1.5 h without prehydration every 21 days. One patient had a partial response (6%; 95% CI 0-26%) lasting
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d05848e5e3842aeaa59cb4c00faf293
https://pubmed.ncbi.nlm.nih.gov/9311439
https://pubmed.ncbi.nlm.nih.gov/9311439
Autor:
R Mante, Claire F. Verschraegen, Andrzej P. Kudelka, Surintip Piamsomboon, Jonh J Kavanagh, Samuel Lifshitz, Wichai Termrungruanglert, Creighton L. Edwards
Publikováno v:
Anti-cancer drugs. 7(5)
High-risk metastatic gestational trophoblastic disease (GTD) in patients who have failed primary chemotherapy has a very poor prognosis. About 25% of women with high-risk metastatic disease become refractory to EMA-CO (etoposide, methotrexate, actino
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09bd7afbf90defb0b1e87322ab7b96c1
https://pubmed.ncbi.nlm.nih.gov/8862714
https://pubmed.ncbi.nlm.nih.gov/8862714
Autor:
Y C, Lin, A P, Kudelka, D, Lawrence, C F, Verschraegen, J J, Kavanagh, C L, Edwards, R, Mante, R S, Freedman
Publikováno v:
European journal of gynaecological oncology. 17(6)
A woman with a refractory locally advanced recurrent cervical cancer was brought to the emergency room because of a life-threatening vaginal hemorrhage from the tumor. She presented with a compromised hemodynamic status that necessitated multiple blo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1f908cdad500c49f642243a64f6afe05
https://pubmed.ncbi.nlm.nih.gov/8971522
https://pubmed.ncbi.nlm.nih.gov/8971522
Autor:
D, Tresukosol, A P, Kudelka, C, Gonzales de Leon, C L, Edwards, R S, Freedman, R, Mante, M, Hord, J J, Kavanagh
Publikováno v:
European journal of gynaecological oncology. 17(3)
The optimal role of paclitaxel in the treatment of epithelial ovarian cancer has not been determined. Dose intense paclitaxel therapy is safe and often recommended as second-line treatment for platinum resistant ovarian cancer. Retreatment with a hig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::127519eaff6ddfd9816e7d5ebbf21dd8
https://pubmed.ncbi.nlm.nih.gov/8780916
https://pubmed.ncbi.nlm.nih.gov/8780916